Mitoxantrone for paediatric cancer raises toxicity concerns: study

It may be ten times more cardiotoxic than doxorubicin
Reuters Health
young child with IV drip in hospital

In paediatric cancer patients, mitoxantrone appears to be at least ten times as cardiotoxic as doxorubicin therapy, while daunorubicin therapy may be less so, according to a large cohort study.

“With 5-year survival of childhood cancer now reaching nearly 85%, balancing the potential long-term adverse effects of otherwise effective cancer treatments is an important consideration,” researchers write in JAMA Oncology.